Filament’s mission is to see safe natural psychedelics in the hands of everyone who needs them as soon as possible. We are a drug discovery and extraction technology company. We turn the compounds held within psychedelic plants into process patent protected GMP extracts for FDA approved medicines.
Advantages of Filament's natural approach vs synthetics
Strong Intellectual Property - There are a limited number of effective ways to extract and purify naturally occuring psychedelic compounds.
Research Potential - Significant research potential of additional compounds occuring naturally within plants individually or in combination creating valuable botanical drugs. Widespread Adoption - The likely avenue for nutraceutical and widespread adoption in uncertain framework. Supply Chain - Consistent, low cost.
Operational 3,500 sq. ft. lab on BCIT Campus. Analysis and pilot manufacturing equipment in place. Initiating pilot GMP Production.
The global psychedelics industry is expected to be worth over USD$100B and represent a healthier, better alternative to the USD $250B spent on mental health treatment in North America.
Ben Lightburn, CEO, Director & Co-Founder
Proven entrepreneur specializing in research, development and commercialization of novel extraction technologies.
Previous CEO of Mazza Innovation; developed and patented water-based extraction process and led C$26M sale to Sensient Technologies
Tom Kineshanko, President, Director & Co-Founder
12 years as a founder, executive, and director in regulated frontier markets; experienced manager and allocator of capital.
Seed round investor in >50 startups from Ethereum to Argo Blockchain that have gone on to over $50B market capitalization
Founder of first licensed Bitcoin asset manager in Canada and swiss hedge fund Protos Asset Management.
Lisa Ranken, P.Eng., M.Eng., Chief Operating Officer
Extensive experience in honing operations, leading teams, and solving complex problems in growing industries with operational expertise in HR, process and workflow design, supply chain management, and R&D.
Designed and built a 35,000 sq. ft. GMP extracts facility at Mazza Innovations and holds two patents.
Warren Duncan, Director of Finance
Experienced capital markets, mergers & acquisitions, and accounting professional with previous CPA designation.
Underwriter on 75+ financings raising ~C$6.5B in aggregate proceeds with significant go-public experience.
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.